An interventional study of Peroneal Nerve Stimulation (PNS) Device in Restless Leg Disorder, Restless Leg Syndrome (RLS) and Pregnancy, sponsored by Rhode Island Hospital. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Rhode Island Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.
Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 75th largest by planned enrollment of the 95 interventional ones that give a count, is one of 4 that started in 2025, is one of 30 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 103rd registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:
Noctrix Health, Inc. · Sites in United States
Ages 21+
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
HBC Immunology Inc · Sites in United States
Ages 18–60
Stanford University · Sites in United States
Ages 18+
Endeavor Health · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 21 · Phase 4 18
First in 1995; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 46 across the 95 interventional studies, 72 across the 12 observational. Of the 83 that completed or were terminated, 35 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 107 have an industry lead sponsor. The 10 most frequent:
Rhode Island Hospital is the lead sponsor of 192 studies on the registry; 37 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Rhode Island Hospital has 1 study filed under Restless Legs Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Restless Legs Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02670161Endeavor HealthQuality Improvement and Practice Based Research in Neurology Using the EMR | 2026-12 |
| NCT07675109Noctrix Health, Inc.Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) | 2026-12 |
| NCT07061470Hugo W. Moser Research Institute at Kennedy Krieger, Inc.A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 107 studies in Restless Legs Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate whether peroneal electrical nerve stimulation (PNS) using the TOMAC™ device is a feasible, acceptable, and safe non-pharmacologic intervention for managing Restless Legs Syndrome (RLS) during pregnancy. This pilot study will also collect preliminary information on symptom relief, sleep quality, and maternal-fetal safety associated with device use.
The main questions the study aims to answer are:
Is TOMAC™ PNS a feasible and acceptable intervention for RLS in pregnant individuals? Are there any maternal, fetal, or neonatal safety concerns with PNS use during pregnancy? What are the patterns of adherence, tolerance, and usability of the TOMAC™ device in this population?
Participants will:
Use a non-invasive TOMAC™ peroneal nerve stimulator during 30-minute sessions as needed, for 8 weeks.
Complete questionnaires assessing feasibility, acceptability, symptom severity, and sleep quality (including AIM, IAM, FIM, IRLS, PGI-I, PSQI, ESS, FOSQ, and MOS-II).
Wear an actigraphy monitor to collect objective sleep data at baseline and at 4 weeks.
Attend scheduled follow-up visits and phone check-ins for maternal vital signs, uterine contraction and fetal monitoring, and neonatal outcome assessment.
This is a prospective, open-label, single-arm pilot study enrolling 15 pregnant participants between 21 and 26 weeks' gestation. Findings will provide the first dataset on the feasibility, acceptability, and safety of TOMAC™ PNS in pregnancy and inform the design of a future randomized controlled trial.
This is a prospective, open-label, single-arm pilot study designed to assess the feasibility, acceptability, and preliminary safety of TOMAC™ peroneal electrical nerve stimulation (PNS) for the treatment of Restless Legs Syndrome (RLS) during pregnancy.
RLS affects approximately 20-30% of pregnant individuals, with symptoms often worsening during the second and third trimesters. It is associated with disrupted sleep, decreased quality of life, and adverse pregnancy outcomes such as gestational hypertension, preeclampsia, prolonged labor, and increased cesarean delivery rates. Pharmacologic therapies for RLS are generally avoided during pregnancy because of limited data on fetal safety, highlighting the need for effective, non-pharmacologic alternatives.
The TOMAC™ system is a non-invasive, wearable, high-frequency peroneal nerve stimulator that delivers bilateral stimulation to the common peroneal nerves. It is FDA De Novo granted for use in adults with moderate to severe RLS but has not been evaluated in pregnant populations. Safety rationale for this study is informed by evidence from other neuromodulation therapies, such as sacral nerve stimulation, which have been used safely during pregnancy without observed maternal or fetal harm.
Primary objectives are to evaluate the feasibility and acceptability of TOMAC™ PNS using validated implementation measures, including the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM).
Secondary objectives include assessment of adherence, dose tolerance, usability, maternal and fetal safety, and exploratory evaluation of symptom improvement and sleep quality through the International Restless Legs Syndrome Rating Scale (IRLS), Patient Global Impression of Improvement (PGI-I), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), and Medical Outcomes Study Sleep Problem Index II (MOS-II).
Fifteen pregnant individuals between 21 and 26 weeks of gestation with a confirmed diagnosis of RLS will be enrolled. Following baseline assessments, participants will undergo an in-person titration session under clinical supervision, which includes uterine contraction and fetal monitoring performed at ≥28 weeks' gestation to ensure maternal and fetal safety.
Participants will then use the TOMAC™ device at home for an 8-week intervention, performing self-administered 30-minute sessions as needed, preferably during periods of symptom distress or prior to sleep.
Data will be collected from patient-reported outcomes, actigraphy sleep recordings, device usage logs, and maternal-fetal safety monitoring. Follow-up includes biweekly phone check-ins, an in-person mid-study visit at week 4, a final in-person visit at week 8, and a three-month postpartum safety follow-up.
This pilot study will generate the first prospective data on the feasibility, acceptability, and safety of peroneal nerve stimulation in pregnancy, providing foundational evidence for future randomized controlled trials evaluating TOMAC™ PNS as a pregnancy-safe, non-pharmacologic treatment for RLS and its potential to improve maternal sleep and pregnancy outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnancy-related:
Neurological and neuromuscular disorders:
Cardiovascular and circulatory conditions:
Dermatological conditions:
Other sleep disorders:
Device and treatment experience exclusions (based on RESTFUL trial criteria):
Other medical conditions:
Other exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive TOMAC™ peroneal nerve stimulation (PNS) therapy for Restless Legs Syndrome (RLS) during pregnancy. Following a supervised in-clinic titration session with uterine contraction and fetal monitoring at ≥28 weeks' gestation, participants will use the device at home for 8 weeks. Each therapy session lasts 30 minutes and can be performed as many times as needed daily, prioritizing periods of high symptom burden or before bedtime. Outcomes include feasibility, acceptability, adherence and maternal-fetal safety.
Device: Peroneal Nerve Stimulation (PNS) Device
The TOMAC™ system is a non-invasive, wearable peroneal nerve stimulator that delivers high-frequency electrical stimulation to the common peroneal nerves at the fibular head. It is FDA-cleared for the treatment of moderate-to-severe Restless Legs Syndrome (RLS) in adults but has not been studied in pregnancy. In this trial, pregnant participants will undergo an in-clinic titration session with uterine contraction and fetal monitoring at ≥28 weeks' gestation to determine comfortable therapeutic intensity. They will then use the device at home for 8 weeks, up to four 30-minute sessions daily, prioritizing periods of high symptom burden or before bedtime. Outcomes will assess feasibility, acceptability, adherence, symptom improvement, sleep quality, and maternal-fetal safety.
Acceptability of Intervention Measure (AIM) Score
The Acceptability of Intervention Measure (AIM) is a validated 4-item questionnaire assessing participants' perceptions of how acceptable the intervention is. Scores range from 1 to 5. Higher scores indicate greater acceptability.
Time frame: Baseline to 8 weeks of intervention
Intervention Appropriateness Measure (IAM) Score
The Intervention Appropriateness Measure (IAM) is a validated 4-item questionnaire assessing participants' perceptions of how appropriate the intervention is for their condition. Scores range from 1 to 5. Higher scores indicate greater appropriateness.
Time frame: Baseline and Week 8 of intervention
Feasibility of Intervention Measure (FIM) Score
The Feasibility of Intervention Measure (FIM) is a validated 4-item questionnaire assessing participants' perceptions of how feasible it is to use the intervention. Scores range from 1 to 5. Higher scores indicate greater feasibility.
Time frame: Baseline and Week 8 of intervention
Adherence to Maximum Allowed Device Sessions
Adherence will be measured as the proportion of actual device sessions used compared to the maximum allowed use (as many as needed 30-minute sessions for 8 weeks). Data will be collected from device logs and participant diaries. Results will be reported as the percentage of completed sessions relative to the maximum allowable sessions.
Time frame: Throughout 8 weeks of intervention
Mean Session Duration
Average duration of each stimulation session, recorded by device logs. Results will be reported in minutes per session.
Time frame: Continuous during 8-week intervention
Mean Stimulation Voltage Used During Device Sessions
Average stimulation voltage delivered by the peroneal nerve stimulation (PNS) device during participant sessions, recorded from device logs. Results will be reported as mean voltage across all sessions.
Time frame: Continuous during 8-week intervention
Number of Participants With Treatment-Related Adverse Events (AEs)
Number of participants experiencing treatment-emergent adverse events related to device use, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Results will be reported as total number of participants.
Time frame: Throughout 8-week intervention
Number of Participants With Serious Adverse Events (SAEs)
Number of participants experiencing serious adverse events related to device use, as assessed by CTCAE v4.0. Results will be reported as total number of participants.
Time frame: Throughout 8-week intervention
Change in Maternal Systolic Blood Pressure
Maternal systolic blood pressure measured at in-clinic visits using automated sphygmomanometer. Results will be reported as mean change in millimeters of mercury (mmHg).
Time frame: Baseline, Week 4, Week 8
Change in Maternal Diastolic Blood Pressure
Maternal diastolic blood pressure measured at in-clinic visits using automated sphygmomanometer. Results will be reported as mean change in millimeters of mercury (mmHg).
Time frame: Baseline, Week 4, Week 8
Change in Maternal Heart Rate
Maternal heart rate measured at in-clinic visits using automated sphygmomanometer. Results will be reported as mean change in beats per minute (bpm).
Time frame: Baseline, Week 4, Week 8
Incidence of Uterine Irritability During Titration
Proportion of participants who experience uterine irritability during the in-clinic titration session (≥28 weeks gestation). Uterine irritability is defined per protocol as ≥10 contractions within a 20-minute period, measured using external tocodynamometry. Results will be reported as percentage of participants.
Time frame: At ≥28 weeks of pregnancy during titration session
Incidence of Fetal Distress During Titration
Proportion of participants who experience fetal distress during the in-clinic titration session (≥28 weeks gestation). Fetal distress is defined as one or more of the following: * FHR bradycardia \<110 bpm for ≥10 minutes * FHR tachycardia \>160 bpm for ≥10 minutes * Minimal/absent variability (\<5 bpm amplitude for ≥20 minutes) * Recurrent decelerations (≥3 late or variable decelerations in 20 minutes) Results will be reported as percentage of participants.
Time frame: At ≥28 weeks of pregnancy during titration session
Incidence of Uterine Irritability Associated With Fetal Distress
Proportion of participants who experience both uterine irritability (≥10 contractions in 20 minutes) and concurrent fetal distress during the same titration session, as defined above. Results will be reported as percentage of participants.
Time frame: At ≥28 weeks of pregnancy during titration session
Infant Birth Weight
Infant birth weight measured at delivery. Results will be reported in grams.
Time frame: At delivery
Neonatal Apgar Score at 1 Minute
Neonatal Apgar score assessed at 1 minute after delivery. Scores range from 0 to 10, with higher scores indicating better neonatal condition. Results will be reported as mean score.
Time frame: At delivery (1 minute)
Neonatal Apgar Score at 5 Minutes
Neonatal Apgar score assessed at 5 minute after delivery. Scores range from 0 to 10, with higher scores indicating better neonatal condition. Results will be reported as mean score.
Time frame: At delivery (5 minutes)
Neonatal Health Outcomes at 3 Months Postpartum
Proportion of infants with adverse health outcomes, including but not limited to growth restriction, feeding difficulties, recurrent hospitalizations, or clinician-diagnosed developmental concerns. Outcomes will be reported as percentage of infants, based on maternal report confirmed by pediatric/OB medical records.
Time frame: 3 months postpartum
Plan to share: No — Individual participant data (IPD) will not be shared because the study is a small pilot with a limited sample size and data will only be used for the purposes outlined in the approved protocol. The IRB-approved consent form does not include provisions for external data sharing.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.
Of 46 non-industry interventional studies with no phase under Restless Legs Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's planned 11 months is below that.
Counting every sponsor, half of 53 studies reached it within 12 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.